MAPLIGHT THERAPEUTICS SHARES DROP 55.7% PREMARKET AFTER CO ANNOUNCES MID-STAGE TRIAL RESULTS FOR SCHIZOPHRENIA DRUG

Reuters · 2d ago

Please log in to view news